Science, explained as simply as possible,
but not simpler
Can a Novel Enzyme Reverse Aging?
Scientists at Revel Pharmaceuticals in the US have developed an artificial enzyme capable of removing undesirable carbohydrate fragments from human proteins. These “sugar-bound” proteins, or advanced glycation end-products (AGEs), accumulate in our bodies as we age. This naturally occurring process, caused by time itself, is linked to impaired protein function and is a key driver of inflammation in older people.
AGEs form when carbohydrates in the body become stably bound to proteins they encounter. The process is similar to the caramelization of meat, or the formation of rust on iron. The result; increased risk of chronic disease in older people, along with the visual changes associated with aging - greying hair, wrinkles etc. Since there are no drugs to reverse the formation of AGEs, they have long been viewed as an inevitable and irreversible consequence of aging. The paper, published in Nature Communications, is a promising first step in challenging that paradigm.
Reversing the Irreversible
Modern machine-learning technologies have allowed the development of new enzymes capable of going where no natural enzyme has gone before. The team used AlphaFold, machine-learning software, to predict the 3D structure of similar natural enzymes that, with modifications, might bind to the bulky AGE molecule and remove the carbohydrate portion from the protein. After scanning 4500 known enzymes, the team identified glycine oxidase (GO), involved in amino acid metabolism in the bacterium Bacillus subtilis, as a suitable candidate. The team focused on reengineering the GO enzyme to recognize a new target, CML - carboxymethyl-lysine, a well studied AGE found abundantly in older humans.
Having chosen a starting enzyme, the team turned to directed evolution, an accelerated mimic of natural selection, to create the new enzyme. To do this, they cloned over 500 million GO variants and selected individuals best able to use CML as an energy supply for bacterial growth. CML is usually a poor growth medium for bacteria, but if they have an enzyme that can split CML into its component parts, the nutrient content in the petri dish is boosted and the bacteria rapidly multiply. By isolating clones that grew the quickest, the team had developed a powerful selection mechanism for identifying their new enzyme.
After each round of selection, the best candidates were subjected to further genetic randomisations to better optimize the CML cleaving activity. Five rounds of directed evolution produced several enzyme variants with the desired activity. Genetic analysis showed that the most effective protein, named CMLase, differed from the original GO enzyme by fifteen amino acid changes and an additional two amino acid deletions.
Into Human Tissue
With the test tube experiments showing promise, the team turned to testing CMLase in human tissue from elderly donors. They reported that CML levels dropped by 78% in lens proteins of the eye, and by 70% in coronary arteries. CML levels in skin collagen, the cause of wrinkles in older people, dropped 55% to levels typically seen in thirty year olds. All told, CMLase removed between 52% and 97% of carbohydrate residues from “older” proteins.
The authors acknowledged several challenges that need to be addressed before the CMLase can move toward testing in humans. These include …
investigating the enzymes ability to penetrate deeper into human tissue.
showing that the functioning of other proteins in the body is not impaired by CMLase activity.
addressing the immunogenicity risk of a protein derived from a bacterium.
Several dozen AGEs have been described in the literature and the authors are hopeful that this approach could be extended beyond CML to other AGE targets.
A team of Canadian and international scientists have begun reconstructing the evolving ecology of the Yukon across several hundred thousand years. The team discovered an unusual, but informative, source of DNA : coprolites - the frozen, fossilized feces preserved in the middens of Arctic ground squirrels. The paper, published in Nature Communications, provides a unique way to study the ancient and evolving ecosystem of the Arctic.
The team used shotgun metagenomics to sequence all DNA found in the coprolite samples. Arctic ground squirrels are not fussy eaters, happily foraging for grasses, seeds, insects, and frequently scavenging from carrion. The rodents deposit their droppings in discrete middens, which first freeze and eventually fossilize, allowing for the preservation of fecal DNA for far longer than in conventional environments.
Study Findings
Thirteen coprolite samples provided an enriched source of ancient environmental DNA - the quality of which often exceeded samples from bone or sediment of similar age.
Researchers identified 200 distinct plant clades; older coprolites contained grass, plantain, sagebrush and sedge, whilst more recent samples included boreal trees like spruce, birch and alder.
All 13 samples contained DNA from large megafauna, including woolly mammoth, steppe bison, Yukon horse, and possibly the extinct American cheetah.
The study described 404 bacterial and archaea genomes not present in surrounding soil controls, suggesting they could have been part of the squirrel's gut microbiome.
The team sequenced 18 mitochondrial genomes, including the ground squirrel, snow hare, bison, and Yukon horse. They will present their woolly mammoth data in a follow-up paper.
The modern Arctic ground squirrel U.parryii replaced the Pleistocene species around 420 000 years ago. The ancient species is more closely related to the modern Eurasian ground squirrel U.undulatus.
The Bottom Line
This study establishes permafrost-preserved coprolites as a high-quality source of ancient environmental DNA, providing a clue to a changing ecological environment over time. With hundreds of ancient middens being identified in the Yukon, more samples should yield a better view of how ground squirrels, the food they ate and the microbes in their guts adapted to an evolving world over nearly 700 000 years.
Discovery of an atmosphere on a trans-Neptunian object
Astronomers in Japan have reported in Nature that a trans-Neptunian object (TNO) orbiting the Sun beyond Pluto may have an atmosphere. This is the first evidence of volatile gas on a small body such as a TNO in the outer solar system.
Statin skeptics are losing the argument
My Op-Ed, published at kevinmd.com, on two meta-analyses showing the safety and efficacy of lipid lowering therapy. Are you concerned about statins? In the past two weeks, cold hard statistics have cut through the fog of misinformation surrounding these best-selling drugs, focusing instead on the safety and efficacy of lowering your blood cholesterol level. No emotions or bias, just numbers. Welcome information for anyone who has enjoyed numerous trips around the sun and is looking forward to many more.
Read more ...
Inflammation & cardiovascular disease: the 2025 ACC Scientific Statement.
The American College of Cardiology has released a scientific statement identifying inflammation as a necessary factor in the development of cardiovascular disease (CVD). It joins the prime suspect, the apoB-containing lipid particles, as an actionable drug target in both primary and secondary populations. The college has called for the widespread adoption of high-sensitivity CRP screening to identify individuals with chronic inflammation, but normal cholesterol, who remain vulnerable to the disease. Read more ...
White Paper - MDMA & chronic pain
Chronic pain affects over 1.5 billion people globally, and is a major contributor to disability, and reduced quality of life. Prolonged opioid-based therapies come with an increased risk of addiction. A non-opioid, non-addictive analgesic is needed to circumvent the short-comings of opioid therapy in a multibillion dollar market .
A new triple drug combination therapy can extend the overall survival time for patients with breast tumours resistant to conventional chemotherapy.
A multinational clinical trial has reported that lepodisiran, a new gene silencing drug, can reduce lipoprotein(a) levels by up to 93.9% compared to placebo.